Badanie Tolwaptanu u niemowląt i dzieci z autosomalnie recesywną wielotorbielowatością nerek (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a rare condition that affects the kidneys, causing them to develop many cysts. This study focuses on infants and children aged 28 days to less than 12 weeks who have been diagnosed with ARPKD. The purpose of the study is to evaluate the safety, tolerability, and effectiveness of a medication called tolvaptan, which is given as an oral suspension. Tolvaptan is a type of drug known as a vasopressin antagonist, which means it works by blocking a hormone that can cause the body to retain water.

The study will observe how tolvaptan affects the need for renal replacement therapy (RRT), a treatment that helps the kidneys function, by the time the children reach one year of age. Participants will receive the medication and be monitored for changes in kidney function and size, as well as overall growth and development. The study will also assess how well the children tolerate the medication and any side effects that may occur.

Throughout the study, various health indicators will be measured, including kidney size, growth patterns, and vital signs. The study aims to provide valuable information on the potential benefits and risks of using tolvaptan in young children with ARPKD, helping to improve treatment options for this challenging condition.